MAIA SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

NEWForm 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 9, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 10, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 11, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 23, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 7, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2025

News

TYPE

HEADLINE

FILED AT

8-K

MAIA Biotechnology Furnishes Investor Presentation and Summary via Form 8-K

Oct 6, 2026

8-K

MAIA Biotechnology, Inc. Announces Results of 2026 Annual Meeting of Stockholders

May 22, 2026

8-K

MAIA Biotechnology Terminates At-The-Market Offering Agreement

May 14, 2026

8-K

MAIA Biotechnology Activates First U.S. Clinical Site for Phase 2 THIO-101 Trial in Advanced NSCLC

Apr 16, 2026

8-K

MAIA Biotechnology Secures $33 Million to Fully Fund Pivotal Phase 3 Trial for Ateganosine

Apr 8, 2026

8-K

MAIA Biotechnology, Inc. Announces Executive Bonus Payments

Apr 2, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

SHARE RESALE REGISTRATION | Shares: 751,879

Oct 7, 2026

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Oct 2, 2026

424B5

TERMINATED/EXPIRED [No Baby Shelf]* May 2026 ATM | Offering amount: $11,200,000 | Bank: H.C. Wainwright & Co.

May 14, 2026

424B5

REGISTERED OFFERING

Mar 4, 2026

424B5

PENDING FIXED PRICE OFFERING | Bank: Konik Capital Partners

Mar 2, 2026

424B5

March 2025 ATM

Mar 26, 2025

Registrations

TYPE

HEADLINE

FILED AT

S-3

SHARE RESALE REGISTRATION EFFECTIVE, DATED 2026-10-06

Sep 25, 2026

S-3

August 2026 SHELF

Aug 21, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Apr 7, 2026

Form D - Notice of Exempt Offering of Securities - Item 06b

Jan 5, 2026

Form D - Notice of Exempt Offering of Securities - Item 06b

Oct 14, 2025

Form D - Notice of Exempt Offering of Securities - Item 06b

Jun 11, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 19, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 27, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 7, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 7, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 8, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 8, 2025

Ownerships

TYPE

HEADLINE

FILED AT

Theagene Jean-Manasse (Reporting)

Oct 2, 2026

Smith Stan (Reporting)

Oct 2, 2026

Luput Cristian (Reporting)

Oct 2, 2026

Louie Ngar Yee (Reporting)

Oct 2, 2026

Guerrero Ramiro (Reporting)

Oct 2, 2026

CHAOUKI STEVEN M (Reporting)

Oct 2, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Oct 7, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 31, 2026

CORRESP

Form CORRESP - Correspondence

Jan 27, 2025

LETTER

Form UPLOAD - SEC-generated letter

Jan 22, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 24, 2023

CORRESP

Form CORRESP - Correspondence

Aug 21, 2023

MAIA Biotechnology, Inc. MAIA · SEC Filings